oral CNS-penetrant AAK1 kinase inhibitor - Bristol-Myers Squibb, Wallingford, CT

oral CNS-penetrant AAK1 kinase inhibitor

in Ph. II for neuropathic pain

from high-throughput screen + opt.

J. Med. Chem.

Bristol-Myers Squibb, Wallingford, CT

Context. BMS-986176/LX-9211 (BMS) is an oral, CNS-penetrable AAK1 kinase inhibitor being developed for treatment of neuropathic pain. There are six main classes of pain medications, NSAIDs, opioids, ion channel…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.